MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) ...

MAIA Biotechnology, Inc.: MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA's Fast Track designation for ateganosine ...
Digital Health

Insights: Cyber resilience and recovery in the NHS

As cyber attacks against healthcare become increasingly inevitable, NHS organisations need to shift from focusing solely on ...
Junior Mining Network

Greenland Resources Signs MOU With German GMH Gruppe for Molybdenum Supply

TORONTO / Jan 19, 2026 / Business Wire / Greenland Resources Inc. (TSX:MOLY, FSE:M0LY) (“Greenland Resources” or the “Company ...
BMJ Open

Adverse childhood experience among patients with severe mood disorders in Gedeo Zone Public Hospitals, Southern Ethiopia:A multisite cross-sectional study

Objective To assess prevalence and associated factors of adverse childhood experiences (ACEs) among patients with severe mood disorders (SMDs). Design An institution-based cross-sectional study.